CMA hits Merck for discounts
Credit: iStock/zorazhuang
The UK’s Competition and Markets Authority has provisionally found that Merck Sharp & Dohme used discounts to restrict competition from biosimilar versions of its drug Remicade.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now